Quantcast

NVS: PARADIGMS Study Shows Benefit Of Gilenya In Children & Adolescents With MS


Shutterstock photo

NVS: PARADIGMS Study Shows Benefit Of Gilenya In Children & Adolescents With MS


(RTTNews.com) - Novartis ( NVS ) said that The New England Journal of Medicine has published full results from the landmark Phase III Gilenya or fingolimod PARADIGMS study, the first-ever controlled, randomized study specifically designed for children and adolescents (aged 10 to 17) with relapsing forms of MS or RMS.

Children and adolescents with MS experience more frequent and often more severe relapses than those seen in adults with MS. The negative effect of relapses on movement, memory and thinking prevents patients from enjoying their childhood and adolescent years to the full, often leaving them feeling isolated and anxious.

PARADIGMS met the primary endpoint of significantly reducing the rate of relapses when compared to interferon beta-1a intramuscular injections over a period of up to two years. The study also met several secondary clinical and imaging endpoints.

Gilenya is a well-established treatment for MS in the adult population, having been used to treat more than 255,000 patients in both clinical trials and the post-marketing setting, with approximately 566,000 years of patient experience.


Read the original article on RTTNews (http://www.rttnews.com/2934413/nvs-paradigms-study-shows-benefit-of-gilenya-in-children-adolescents-with-ms.aspx)


For comments and feedback: contact editorial@rttnews.com




This article appears in: Stocks
Referenced Symbols: NVS



More from RTT News

Subscribe






See All RTT news











Research Brokers before you trade

Want to trade FX?